What is BPDCN?
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare blood cancer. Each year, there are 1000 to 1400 newly diagnosed cases in the United States and Europe combined, and 3 out of 4 diagnosed patients are men.1 BPDCN often first appears as an unusual growth or change in appearance on the skin (also called a skin lesion), and may involve lymph nodes, blood, and bone marrow.
- Up to 90% of patients with BPDCN show skin lesions 2-4
- A molecule called CD123 is highly expressed on BPDCN cells. CD123 is important for the diagnosis of BPDCN and is a target for drugs to treat the disease2,5,6
BPDCN IS AN AGGRESSIVE CANCER.1 IF YOU OR SOMEONE YOU LOVE HAS BEEN DIAGNOSED, CONSIDER DISCUSSING CLINICAL TRIAL PARTICIPATION WITH YOUR DOCTOR.
Why participate in a clinical trial?
Clinical trials are research studies. The goal of clinical trials is to find new ways to treat a disease or a condition. Your participation in this trial may help doctors learn more about your type of cancer and how to treat it. The information learned from clinical trials may be useful to future patients and researchers.
IMGN632 is designed to target CD123-positive cancer cells while sparing normal cells from toxicity. IMGN632 is a type of drug called an antibody-drug conjugate (ADC). IMGN632 is being studied in patients with BPDCN. The clinical trial is open and enrolling at several sites in the US and Europe.
aIMGN632 is an investigational drug not approved by the US Food and Drug Administration or any other health authority. The safety and efficacy of IMGN632 has not been determined.
About the clinical Trial
- Every patient who participates in the trial will receive the study drug (IMGN632); there is no placebo in this study
- Patients will receive IMGN632 once every 3 weeks
- IMGN632 can be administered by your study doctor in either an outpatient setting or in the hospital (your doctor will let you know what is best for you)
- There are no additional costs to patients for participating in the study (beyond those associated with your usual care). Travel reimbursement may be available; the study costs are being paid for by ImmunoGen, Inc., the sponsor of the study
Who may be eligible?
Patients who are at least 18 years old
Patients diagnosed with CD123-positive BPDCN
Your doctor will discuss all of the criteria that will determine whether or not you are eligible for this study. You may also visit clinicaltrials.gov to learn more about the trial
TO DISCUSS ELIGIBILITY FOR THE CLINICAL TRIAL, CONTACT YOUR NEAREST CENTER DIRECTLY, OR SPEAK WITH YOUR HEALTHCARE PROFESSIONAL.
Click or tap to show/hide contact information.
For more information, talk to your doctor, or contact one of these study locations about participating in the study, or contact ImmunoGen Medical Affairs at 781-895-0600 or email@example.com.
CAUTION: NEW DRUG—LIMITED BY FEDERAL (OR UNITED STATES) LAW TO INVESTIGATIONAL USE
References: 1. Leukemia & Lymphoma Society. Facts about blastic plasmacytoid dendritic cell neoplasm (BPDCN). Revised July 2019. Accessed March 22, 2021. https://www.lls.org/sites/default/files/National/USA/Pdf/Publications/FSHP2_BPDCN_FINAL_2019.pdf. 2. Laribi K, Denizon N, Besançon A, et al. Blastic plasmacytoid dendritic cell neoplasm: from origin of the cell to targeted therapies. Biol Blood Marrow Transplant. 2016;22(8):1357-1367. 3. Sullivan JM, Rizzieri DA. Treatment of blastic plasmacytoid dendritic cell neoplasm. Hematology Am Soc Hematol Educ Program. 2016(1);16-23. 4. Julia F, Petrella T, Beylot-Barry M, et al. Blastic plasmacytoid dendritic cell neoplasm: clinical features in 90 patients. Br J Dermatol. 2013;169(3):579-586. 5. Facchetti F, Cigognetti M, Fisogni S, et al. Neoplasms derived from plasmacytoid dendritic cells. Mod Pathol. 2016;29(2):98-111. 6. Pagano L, Giovanna Valentini C, Pulsoni A, et al. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. Haematologica. 2013;98(2):239-246.